glp 1 is semaglutide Comparing Ozempic, Wegovy and Other GLP-1 Drugs Semaglutide vs. Other GLP-1 Receptor

In December 2024, NICE recommended the use of tirzepatide (Mounjaro), alongside semaglutide (Wegovy) and liraglutide (Saxenda), for the treatment of weight-related comorbidities.10 NICE recommended these drugs alongside diet and exercise, yet many patients lack structured programs offering nutritional, behavioural, and psychological support

Moreover, under oxidative stress, although autophagy initiation signals are activated in granulosa cells, impaired lysosomal acidification and mitophagy defects disrupt autophagic flux (Xu G

[PMC free article: PMC296716] [PubMed: 2195062] 114

Nonetheless, more longitudinal and adequately powered studies are needed to determine their long-term efficacy on cognitive trajectories in this population

Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce body weight, glycaemia, blood pressure, postprandial lipaemia and inflammation actions that could contribute to the reduction of cardiovascular events